Breaking news

Cyprus Study Uncovers Cellular Shield For Cancer & Genetic Disorders

A pioneering study from the University of Cyprus’s Laboratory of Cellular and Developmental Biology, in partnership with the University of Oxford, is set to redefine medical treatment paradigms. Published in Science Advances, the research uncovers a previously unknown mechanism by which cells fortify their nuclei against external mechanical forces—a discovery with profound implications for cancer treatment and rare genetic disorders.

Redefining Cellular Defense

Traditionally recognized for its role in DNA repair, the ATR protein has now been found to perform an additional, critical function. Researchers demonstrated that ATR relocates to the nuclear envelope, where it triggers the formation of a protective protein network known as nuclear actin. This reinforcement acts as an internal shield, safeguarding the nucleus from mechanical stress—particularly vital in tissues like the lungs, heart, and muscles that are constantly subjected to physical forces.

Read From Research to Reality: Cyprus’ Role In Creating Virtual Twins For Next-Gen Medicine

Transformative Medical Applications

The clinical potential of this breakthrough is immense. Diseases characterized by nuclear fragility—such as certain aggressive cancers, muscular dystrophies, and rare conditions like progeria—could be tackled more effectively by targeting this newly discovered pathway. By enhancing the resilience of the cell nucleus, future therapies might better prevent metastasis in cancer patients and improve outcomes in gene therapies aimed at correcting genetic disorders.

Lead author Dr. Maria Chatzifrangkeskou summed up the study’s significance:

“Our research highlights a crucial cellular mechanism that could serve as the foundation for new treatments in diseases where the nucleus is particularly vulnerable.”

A Catalyst for Future Innovations

This breakthrough not only expands our understanding of cellular biology but also positions Cyprus at the forefront of medical innovation. As scientists shift focus from traditional in vitro methods to in silico models—where large datasets power dynamic simulations of the human body—the implications extend beyond cancer therapy to a broader spectrum of diseases driven by nuclear instability.

Cypriot researchers are already making significant contributions to this field, bolstering the country’s reputation as a key player in Europe’s innovation ecosystem. By pushing the boundaries of how we model and treat complex biological systems, this study offers a glimpse into a future where personalized, predictive medicine is within reach.

This transformative discovery not only redefines how we perceive cellular protection but also opens new avenues for therapies that could change countless lives. With Cyprus leading the charge, the journey from research to revolutionary treatment is well underway.

Greek And Cypriot Banks Propel Economic Growth With Aggressive Credit Expansion

Robust Q1 Growth Sets The Stage

Banks in Greece and Cyprus are accelerating lending activity, with total credit expansion projected to approach or exceed €15 billion in 2026. The increase is reinforcing the banking sector’s role in supporting profitability and broader economic growth across the region.

Targeted Lending Initiatives And Sector Performance

According to reports by Greek business outlet Newmoney, banks are increasingly relying on credit expansion to sustain earnings growth as interest rate dynamics shift across Europe. First-quarter results already point to strong momentum in lending activity.

Eurobank has set a target of €3.8 billion in credit expansion this year. National Bank of Greece and Piraeus Bank are each targeting €3 billion, while Alpha Bank aims for €3.5 billion. Smaller lenders are also expanding aggressively, with CrediaBank targeting €1.2 billion and Optima Bank aiming for €1.1 billion.

Notable Banking Results Across Markets

First-quarter results underline the scale of the lending rebound. Banks that have reported Q1 figures recorded cumulative credit expansion of €4.7 billion. Piraeus Bank increased its loan portfolio to €38.6 billion, while net credit expansion reached €1.3 billion across major business segments. At National Bank of Greece, new loan disbursements rose 50%, contributing to net credit expansion of €500 million.

Meanwhile, Eurobank reported a 9.8% increase in net credit expansion to €1.1 billion. In Cyprus, Bank of Cyprus recorded Q1 lending of €829 million, up 9% compared with the end of 2025, while Optima Bank posted a 27% year-on-year increase in loan disbursements to €1 billion.

Sectoral Dynamics And Asset Quality Improvements

A recent report from UBS showed that business lending remained the strongest growth driver in March, increasing 10.9% year-on-year. Consumer lending rose 7.7%, while housing loans increased 1.1%. Asset quality also continued to improve. Non-performing loans declined to 3.3% in Q4 2025, down 30 basis points from the previous quarter, reflecting the sector’s ongoing balance-sheet clean-up.

Despite the strong lending momentum, profitability remained broadly stable in the first quarter. Combined net profits at major banks, including National Bank of Greece, Piraeus Bank, Eurobank, Optima Bank and Bank of Cyprus, totaled €1.12 billion, representing a marginal year-on-year decline of 0.27%.

Profitability And Revenue Breakdown

Profit trends varied across institutions during the quarter. Net profit at National Bank of Greece declined 9.9%, while Piraeus Bank reported a 1.42% decrease. By contrast, Eurobank increased profitability by 5.3%. In Cyprus, Bank of Cyprus reported a 3% increase in profit, while Optima Bank posted a 22% rise. Across the sector, net interest income increased 1.4% to €1.93 billion, although performance differed among individual banks. Fee income recorded stronger growth, rising 20% year-on-year to €590 million.

Long-Term Trends And Strategic Impact

Over the past year, listed banks in Greece and Cyprus generated combined post-tax profits of €5.458 billion, up 15.4% from the previous year. During the same period, net interest income declined 4.2% to €9.307 billion, reflecting pressure from changing rate conditions.

Balance-sheet quality continued to strengthen as non-performing loans fell to €5.7 billion, down 5.2% compared with December 2024. Since March 2016, banks in the two markets have reduced non-performing exposures by an estimated €101.5 billion, equivalent to a cumulative decline of 94.7%.

The sustained improvement in asset quality, combined with expanding loan portfolios, is reinforcing the sector’s role in financing business activity and economic recovery across Greece and Cyprus.


Aretilaw firm
The Future Forbes Realty Global Properties
Uol
eCredo

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter